AstraZeneca is making a bold genomics play that places it at the forefront of the precision medicine game: Company-wide, it’s going to use data insights from a huge swath of genomes to inform the future of its drug development.
{iframe}http://medcitynews.com/2016/04/astrazeneca-j-craig-venter/?utm_source=MedCity+News+Subscribers&utm_campaign=3d3cb500d9-MCN+Daily+Email&utm_medium=email&utm_term=0_5092836c41-3d3cb500d9-408826397{/iframe}